Wall Street analyst estimates for Caris Life Sciences, Inc. (CAI): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 6 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 7 |
| Avg rating (1-5) | 0.86 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-04 | $0.03 | ||
| 2026-08-05 | $-0.00 | $0.01 | -139.2% |
| 2026-05-07 | $-0.00 | $-0.02 | +91.0% |
| 2026-02-26 | $0.28 | $0.01 | +2700.0% |
| 2025-11-05 | $0.08 | $-0.08 | +200.0% |
| 2025-08-12 | $-0.54 | $-0.21 | -157.1% |
| 2025-06-09 | $-0.35 | $-0.22 | -60.3% |
| 2021-11-05 | $2.95 | $0.61 | +383.6% |
Valuation Ratios
| P/E Ratio | 76.10 |
| Price / Book | 13.53 |
| EV / EBITDA | 48.37 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $249.7M | $294.4M | $348.4M | $432.1M | $416.5M | $294.0M | $258.5M | $306.1M | $412.3M | $812.0M |
| Cost of Revenue | $123.8M | $156.9M | $179.1M | $218.5M | $216.0M | $109.9M | $178.5M | $216.8M | $233.5M | $272.9M |
| Gross Profit | $125.9M | $137.5M | $169.3M | $213.6M | $200.5M | $184.2M | $80.0M | $89.3M | $178.8M | $539.2M |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | $101.3M | $116.9M | $113.9M | $45.3M |
| Selling, General & Admin | $27.6M | $35.7M | $42.7M | $50.3M | $52.7M | $27.3M | $294.5M | $291.5M | $321.9M | $392.5M |
| Operating Expenses | $57.8M | $71.5M | $63.6M | $64.8M | $70.2M | $45.1M | $395.8M | $408.9M | $435.9M | $494.1M |
| Operating Income | $68.1M | $66.0M | $105.7M | $148.8M | $130.3M | $139.1M | -$315.8M | -$319.6M | -$257.1M | $45.1M |
| EBITDA | $181.4M | $159.3M | $223.5M | $283.3M | $248.3M | $254.5M | -$245.9M | -$260.8M | -$183.0M | $11.4M |
| Interest Expense | $36.0M | $42.8M | $53.1M | $78.3M | $79.2M | $61.6M | $26.7M | $31.6M | $50.0M | $56.9M |
| Pre-tax Income | $31.2M | $9.9M | $57.2M | $81.5M | $55.2M | $29.5M | -$320.8M | -$341.4M | -$281.9M | -$68.1M |
| Income Tax | $4.3M | $3.8M | -$14.9M | $2.9M | $4.2M | $1.8M | 0 | 0 | 0 | $469.9M |
| Net Income | $26.8M | $6.0M | $72.1M | $78.6M | $31.0M | $27.7M | -$320.8M | -$341.4M | -$281.9M | -$538.0M |
| EPS | $1.29 | $0.31 | $3.74 | $3.97 | $1.72 | $1.55 | $-1.57 | $-1.82 | $-2.70 | $-1.91 |
| EPS (Diluted) | $1.28 | $0.31 | $3.68 | $3.97 | $1.72 | $1.55 | $-1.57 | $-1.82 | $-2.70 | $-1.86 |
| Shares Outstanding (Diluted) | $21.0M | $19.4M | $19.6M | $19.8M | $18.0M | $17.9M | $254.8M | $254.7M | $254.7M | $289.9M |
Price
| Price | $30.39 |
| Market Cap | $8.6B |
| Exchange | NASDAQ |
| Country | US |
Related companies: ABVX · CORT · CYTK · HALO · JAZZ · MDGL · MRNA
Explore sector: Healthcare · Biotechnology
More sections of CAI: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks